Trials / Completed
CompletedNCT02629172
Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1
Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,043 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 120 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir used for patients infected with HCV genotype 1 in daily practice in Japan.
Conditions
Timeline
- Start date
- 2016-01-05
- Primary completion
- 2019-02-28
- Completion
- 2019-02-28
- First posted
- 2015-12-14
- Last updated
- 2020-02-24
Locations
388 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02629172. Inclusion in this directory is not an endorsement.